Covered recipient · General Payments record
ROBERT HAYES CRAWFORD
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2020–2024
$1,316.24
- Reported across 73 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $349.74 | 18 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $85.02 | 4 |
| Novo Nordisk AS | $81.46 | 4 |
| PFIZER INC. | $60.93 | 3 |
| GlaxoSmithKline, LLC. | $50.74 | 3 |
| Lilly USA, LLC | $41.13 | 2 |
| Acerta Pharma LLC | $16.26 | 1 |
| IDORSIA PHARMACEUTICALS US INC | $14.20 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $15.14 | 01/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115537214 | CMS |
| Amgen Inc. | $23.71 | 07/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115537226 | CMS |
| Amgen Inc. | $20.52 | 10/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115537235 | CMS |
| Amgen Inc. | $25.65 | 11/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115537245 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.26 | 04/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105659170 | CMS |
| GlaxoSmithKline, LLC. | $17.88 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116312532 | CMS |
| GlaxoSmithKline, LLC. | $15.31 | 03/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116354223 | CMS |
| GlaxoSmithKline, LLC. | $17.55 | 11/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116267237 | CMS |
| IDORSIA PHARMACEUTICALS US INC | $14.20 | 04/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146775572 | CMS |
| Lilly USA, LLC | $18.69 | 08/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135369344 | CMS |
| Lilly USA, LLC | $22.44 | 09/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135393563 | CMS |
| Novo Nordisk Inc | $16.39 | 03/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097292526 | CMS |
| Novo Nordisk Inc | $18.46 | 04/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096756437 | CMS |
| Novo Nordisk Inc | $20.74 | 08/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097417920 | CMS |
| Novo Nordisk Inc | $25.87 | 09/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097648791 | CMS |
| PFIZER INC. | $20.81 | 03/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131490986 | CMS |
| PFIZER INC. | $19.70 | 05/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131506159 | CMS |
| PFIZER INC. | $20.42 | 11/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131499313 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2020, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.